Drug or treatment

Toripalimab clinical trials

• 121Clinical trials
• 3New in 30 days
• 9Countries

Newest trials

All recruiting trials (121)

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Propranolol with Toripalimab and Platinum Chemo before/around surgery in NSCLC

  This study tests whether adding propranolol to toripalimab and platinum-based chemotherapy is safe and tolerable for people with resectable non-small cell lung cancer before surgery.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07886229

• Neoadjuvant Cryo-Thermal Ablation with Toripalimab and Chemo for Resectable NSCLC

  This study tests whether using Cryo-Thermal Ablation before chemo-immunotherapy helps people with resectable NSCLC see better outcomes.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan and 8 other locations · NCT07855965

• Rimegepant plus toripalimab in advanced urothelial cancer after standard therapy

  This small, early-stage study tests whether combining rimegepant with toripalimab is safe and shows signs of activity in adults with advanced urothelial cancer that did not respond to prior treatment.

  Recruiting at 2 sites Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 1 other locations · NCT07835035

• SABR with Axitinib and Toripalimab for oligometastatic kidney cancer

  This phase 2 trial tests whether giving SABR radiation together with axitinib and toripalimab can shrink tumors and help patients with up to five metastatic sites from clear cell renal cell carcinoma.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07744932

• Immune Sandwich: Induction with Nimotuzumab and Toripalimab Plus Radiotherapy vs Full-Course Immunotherapy for Advanced Nasopharyngeal Cancer

  This trial tests whether a shortened, targeted immunotherapy plan added to chemoradiation can match the full immunotherapy approach for locally advanced nasopharyngeal cancer in adults 18–70.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07706985

• Predicting Toripalimab Response in High-Risk Recurrent Renal Cell Carcinoma using MRD

  This study tests whether measuring minimal residual disease after surgery can predict which high-risk RCC patients will benefit from adjuvant Toripalimab.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07657325

• Enfortumab Vedotin plus Toripalimab vs Gemcitabine-Cisplatin as Neoadjuvant Therapy for Locally Advanced or High-Risk Muscle-Invasive Bladder Cancer

  This study tests if Enfortumab Vedotin with Toripalimab before surgery helps patients with locally advanced or high-risk muscle-invasive bladder cancer, compared with the standard Gemcitabine plus Cisplatin.

  Recruiting Phase 2 Peking University Third Hospital · Beijing, Beijing Municipality · NCT07647289

• Intratumoral EDS01 plus toripalimab for recurrent or metastatic head and neck cancer

  This phase 1 study tests whether directly injecting a gene‑therapy endostatin product (EDS01) into a tumor, together with the PD-1 inhibitor toripalimab, is safe and shows early signs of activity in adults with recurrent or metastatic head and neck cancer after platinum therapy.

  Recruiting Phase 1 West China Hospital · Chengdu, China · NCT07625423

• First-line treatment for biliary tract cancer with iparomlimab, toripalimab, bevacizumab and chemotherapy

  This study tests a combination of iparomlimab and toripalimab with bevacizumab and chemotherapy as the first treatment approach for advanced biliary tract cancer.

  Recruiting Phase 4 Huazhong University of Science and Technology · Wuhan, Hubei · NCT07619235

• JS107 plus toripalimab and chemotherapy as first-line treatment for CLDN18.2-positive gastric cancer

  This trial tests whether JS107 added to toripalimab and XELOX is better than a similar regimen with sintilimab for patients with untreated, CLDN18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma.

  Recruiting Phase 3 NingBo Junyan Hongshi Biosciences Co., Ltd · Guangzhou, Guangdong · NCT07584135

• Perioperative toripalimab plus lenvatinib for multi-stage clear cell kidney cancer

  This trial tests whether giving toripalimab with lenvatinib before surgery helps shrink or kill tumors in people with localized, locally advanced, or metastatic clear cell kidney cancer.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07571551

• Compared immunotherapy timings in resectable stage II-IIIA NSCLC

  In people with resectable stage II-IIIA non-small cell lung cancer, this study will test three timing approaches of the anti-PD-1 therapy toripalimab to see which works best when given around surgery.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07554846

• Toripalimab plus doctor‑chosen chemotherapy for advanced HER2‑negative breast cancer

  This trial will test whether adding the PD‑1 drug toripalimab to a chemotherapy regimen chosen by your doctor helps people with recurrent or metastatic HER2‑negative breast cancer who have already had prior systemic therapy.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT07540533

• IPG7236 With Toripalimab in Advanced Solid Tumors

  This study tests IPG7236 combined with toripalimab in adults with advanced solid tumors to see if the combination is safe and possibly effective.

  Recruiting Phase 1/2 Nanjing Immunophage Biotech Co., Ltd · Shanghai, PuDongXinQu · NCT07508761

• Short-course radiotherapy then CapeOX and toripalimab, with or without surufatinib, before surgery for high-risk mid-to-low rectal cancer

  This trial tests whether adding surufatinib to short-course radiotherapy followed by CapeOX chemotherapy plus toripalimab before surgery improves tumor response in adults with high-risk mid-to-low rectal cancer.

  Recruiting Phase 2/3 The First Hospital of Jilin University · Changchun, Jilin · NCT07505472

• Short-course SBRT plus toripalimab and chemotherapy for chemo-resistant triple-negative breast cancer

  This trial will try a short, high-precision course of breast radiation followed by toripalimab with paclitaxel and carboplatin for people whose triple-negative breast cancer did not shrink after initial chemotherapy to see if it can eliminate invasive cancer at surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07457359

• AL8326 plus toripalimab for advanced solid tumors

  This study will test whether taking AL8326 tablets together with toripalimab is safe and helps adults with advanced or metastatic solid tumors who have progressed after or have no standard treatment options.

  Recruiting at 15 sites Phase 1/2 Advenchen Laboratories, LLC · Beijing, Beijing Municipality and 14 other locations · NCT07392736

• Neoadjuvant trastuzumab rezetecan plus toripalimab for HR‑positive, HER2‑low breast cancer

  This trial will test whether giving trastuzumab rezetecan with toripalimab before surgery helps people with HR‑positive/HER2‑low breast cancer shrink tumors and achieve complete responses.

  Recruiting at 5 sites Phase 2 First Affiliated Hospital of Zhejiang University · Harbin and 4 other locations · NCT07383818

• Toripalimab with three platinum-based induction chemotherapies for locally advanced nasopharyngeal carcinoma

  This trial tests whether adding toripalimab to one of three different platinum-based induction chemotherapy regimens before standard concurrent chemoradiotherapy can improve outcomes for adults with locally advanced nasopharyngeal carcinoma.

  Recruiting at 4 sites Phase 2 Sun Yat-sen University · Dongguan, Guangdong and 3 other locations · NCT07362979

• LM-108 plus toripalimab versus paclitaxel for CCR8-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

  This trial tests whether adding LM-108 (an anti-CCR8 antibody) to the PD-1 blocker toripalimab works better than paclitaxel for adults with CCR8-positive advanced or metastatic gastric or GEJ adenocarcinoma after first-line therapy.

  Recruiting Phase 3 LaNova Medicines Limited · Beijing, Beijing Municipality · NCT07362186

• Nimotuzumab plus toripalimab and chemotherapy for locally advanced tonsillar cancer

  This trial will try giving nimotuzumab and toripalimab together with chemotherapy before surgery to see if it increases complete tumor response in people with resectable, locally advanced tonsillar cancer.

  Recruiting Phase 2 Tang-Du Hospital · Shanxi, Province · NCT07353723

• Low-dose radiotherapy with toripalimab and chemotherapy for recurrent or metastatic nasopharyngeal cancer

  This will test whether adding low-dose radiotherapy to toripalimab plus gemcitabine‑cisplatin helps people with recurrent or metastatic nasopharyngeal cancer respond better while staying safe.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07325539

• Combining 9MW2821 with toripalimab around surgery for urothelial cancer

  This trial tests whether giving 9MW2821 together with toripalimab before and after surgery helps adults with non-metastatic urothelial cancer.

  Recruiting Phase 2 Mabwell (Shanghai) Bioscience Co., Ltd. · Guangzhou, Guangdong · NCT07314723

• Toripalimab plus BCG bladder instillation after TURBT for high‑risk non‑muscle‑invasive bladder cancer

  This trial will test whether adding toripalimab (a PD‑1 immunotherapy) to BCG bladder instillations after TURBT helps people with high‑risk or very high‑risk non‑muscle‑invasive bladder cancer.

  Recruiting Phase 2 Changhai Hospital · Shanghai, Shanghai Municipality · NCT07307456

• Toripalimab plus standard treatment for HPV-positive throat cancer

  This trial tests whether adding toripalimab to chemotherapy followed by surgery or lower-dose radiation can help adults with HPV16-positive, locoregionally advanced oropharyngeal (throat) cancer.

  Recruiting Phase 2 University of Chicago · Chicago, Illinois · NCT07290621

• Neoadjuvant immunotherapy with Dupilumab and Toripalimab for MSS colorectal cancer with resectable liver metastases

  This study tests a pre-surgery treatment combining dupilumab and toripalimab in adults with microsatellite-stable colorectal cancer that has liver metastases, to see if it’s safe and can lead to major tumor response.

  Recruiting Phase 1/2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07277322

• YL201 with toripalimab, with or without cisplatin, for recurrent or metastatic nasopharyngeal carcinoma

  This trial tests whether adding the experimental drug YL201 to toripalimab, with or without cisplatin, can help people with recurrent or metastatic nasopharyngeal carcinoma.

  Recruiting Phase 1/2 MediLink Therapeutics (Suzhou) Co., Ltd. · Chongqing, Chongqing Municipality and 19 other locations · NCT07258979

• StratifiedToripalimab Consolidation After Chemoimmunotherapy and CCRT in Unresectable ESCC

  This trial tests whether giving toripalimab after chemoimmunotherapy and chemoradiation helps people with unresectable locally advanced esophageal squamous cell carcinoma to see if they benefit more than observation.

  Recruiting Phase 3 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07246330

• Induction therapy with toripalimab plus cisplatin and docetaxel for head and neck squamous cell carcinoma

  This study tests whether adding toripalimab to cisplatin and docetaxel induction therapy is safe and tolerable for adults with newly diagnosed locally advanced head and neck squamous cell carcinoma.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07214987

• Toripalimab plus capecitabine after chemoradiotherapy for esophageal squamous cell carcinoma

  This trial will test whether giving toripalimab together with low‑dose capecitabine after definitive chemoradiotherapy helps people with locally advanced esophageal squamous cell carcinoma live longer and have fewer recurrences.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07177794

• Pre-surgery targeted artery embolization plus toripalimab and axitinib for advanced kidney cancer

  This test tries a targeted artery embolization one week before starting toripalimab plus axitinib to shrink advanced kidney tumors and improve outcomes for people preparing for surgery.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07172386

• Toripalimab to lower recurrence after surgery for mismatch repair–deficient stage IIB–III colon cancer

  This trial tests whether toripalimab given after surgery can lower the chance of cancer coming back in people with mismatch repair–deficient stage IIB–III colon cancer.

  Recruiting at 5 sites Phase 2 Emory University · Atlanta, Georgia and 4 other locations · NCT07140679

• Toripalimab with induction chemo, radiation, and Omega-3 for locally advanced nasopharyngeal cancer

  This study tests whether adding toripalimab and Omega-3 to induction chemotherapy and radiation helps patients with locally advanced nasopharyngeal carcinoma.

  Recruiting at 2 sites Phase 2 Affiliated Hospital of Guangdong Medical University · Zhanjiang, Guangdong and 2 other locations · NCT07136519

• SHR-A1811 plus SHR-1316 as first-line treatment for PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer

  This will test whether SHR-A1811 combined with SHR-1316 as first-line therapy helps people with PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer live longer without their cancer getting worse compared with toripalimab plus nab‑paclitaxel.

  Recruiting at 2 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07111832

• Second-line therapy with Ongericimab and Toripalimab plus bevacizumab and chemotherapy in advanced MSS/pMMR colorectal cancer

  This study tests a second-line treatment that combines Ongericimab and Toripalimab with bevacizumab and chemotherapy for adults with advanced MSS/pMMR colorectal cancer who have progressed after first-line therapy.

  Recruiting Phase 2 Shanghai Pudong Hospital · Shanghai, Shanghai Municipality · NCT07106034

• LBL-024 alone or combined with LBL-007 or toripalimab for advanced melanoma

  This research will test whether LBL-024, given alone or with LBL-007 or with the PD-1 drug toripalimab, helps people with advanced melanoma.

  Recruiting at 10 sites Phase 1/2 Nanjing Leads Biolabs Co.,Ltd · Beijing, Beijing Municipality and 15 other locations · NCT07099430

• Sacituzumab Tirumotecan plus Toripalimab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma

  This trial will test whether the antibody-drug conjugate sacituzumab tirumotecan combined with the PD-1 inhibitor toripalimab helps people with recurrent or metastatic head and neck squamous cell carcinoma whose tumors are Trop-2 positive and have PD-L1 CPS ≥1.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07088211

• Regorafenib with toripalimab and albumin‑bound paclitaxel for third‑line advanced pancreatic cancer

  This trial will test whether adding regorafenib to toripalimab and albumin‑bound paclitaxel helps people with unresectable or metastatic pancreatic cancer who have already received two prior lines of therapy.

  Recruiting Phase 1/2 Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Shenzhen, Guangdong · NCT07040228

• Toripalimab plus chemotherapy as additional treatment after surgery for non-small cell lung cancer

  This tests whether adding toripalimab to cisplatin-based chemotherapy after complete surgical removal helps people with resected Stage IB–IIIB non-small cell lung cancer stay cancer-free longer.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07039656

• Combination therapy for advanced triple-negative breast cancer

  This study is testing a new combination of two drugs to see if it can help people with advanced triple-negative breast cancer live longer and feel better.

  Recruiting Peking University Cancer Hospital & Institute · Beijing · NCT06991790

• Personalized vaccine for preventing relapse in acute myeloid leukemia

  This study is testing a personalized vaccine to see if it can help prevent relapse in people with acute myeloid leukemia who are in remission but still have some cancer cells left.

  Recruiting Early Phase 1 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT06980155

• Neoadjuvant chemotherapy with Toripalimab for HR+/HER2- breast cancer

  This study is testing if adding a new immunotherapy drug called Toripalimab to standard chemotherapy can help people with HR+/HER2- breast cancer respond better to treatment.

  Recruiting at 2 sites Phase 3 First Affiliated Hospital of Zhejiang University · Hangzhou and 12 other locations · NCT06977893

• Combining STC-15 with Toripalimab for Advanced Cancers

  This study is testing whether combining a new cancer drug, STC-15, with toripalimab can help people with advanced cancers feel better and improve their treatment outcomes.

  Recruiting at 11 sites Phase 1/2 STORM Therapeutics LTD · San Francisco, California and 13 other locations · NCT06975293

• Combining toripalimab and endostatin for treating stage II melanoma

  This study is testing if combining a new cancer drug with another treatment can help people with stage II melanoma live longer without their cancer coming back after surgery.

  Recruiting at 4 sites Phase 2 Fudan University · Shanghai, Shanghai Municipality and 3 other locations · NCT06965231

• Combining high-intensity focused ultrasound with immunotherapy and chemotherapy for breast cancer treatment

  This study is testing if combining high-intensity focused ultrasound with immunotherapy and chemotherapy can help women with a specific type of breast cancer more than just chemotherapy alone.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06964906

• Toripalimab plus carboplatin and docetaxel before surgery for sinonasal cancer

  This study tests whether giving toripalimab with carboplatin and docetaxel before surgery helps people with locally advanced sinonasal cancers.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06940180

• Pre‑surgery SBRT followed by nab‑paclitaxel plus toripalimab for HR+/HER2− breast cancer

  This trial will test whether a short course of targeted radiotherapy before surgery, followed by reduced chemotherapy with nab‑paclitaxel and the immunotherapy toripalimab, can raise the chance of a complete tumor response in women with stage IIB–IIIC HR‑positive, HER2‑negative breast cancer.

  Recruiting at 2 sites Phase 2 Xijing Hospital · Xi'an, Shannxi Province and 1 other locations · NCT06914440

• Combination of Toripalimab and Celecoxib for Advanced Colorectal Cancer

  This study is testing if a combination of two medications, Toripalimab and Celecoxib, can help patients with advanced colorectal cancer avoid surgery and improve their treatment outcomes.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06903858

• Combining radiation therapy with targeted and immunotherapy for advanced kidney cancer

  This study is testing a new treatment that combines radiation therapy with two other medications to see if it helps people with advanced kidney cancer live longer without their disease getting worse.

  Recruiting Phase 2 Peking University First Hospital · Beijing, Beijing Municipality · NCT06889649

• LM-168 alone or combined with toripalimab for advanced solid tumors

  This trial tests whether LM-168, given alone or together with the immunotherapy toripalimab, can shrink tumors or control disease in adults with advanced solid tumors.

  Recruiting at 5 sites Phase 1/2 LaNova Medicines Limited · Ryde, New South Wales and 5 other locations · NCT06868199

• Combination treatment for advanced intrahepatic cholangiocarcinoma and gallbladder cancer

  This study is testing a new combination treatment for people with advanced bile duct and gallbladder cancer to see if it can help them respond better to therapy and possibly become eligible for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tia · NCT06852287

• Treatment for advanced nasopharyngeal carcinoma using targeted therapy and immunotherapy.

  This study is testing a new combination of targeted therapy and immunotherapy with chemotherapy to see if it helps people with advanced nasopharyngeal cancer live longer without their disease getting worse.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06851247

• Combining Toripalimab with Chemoradiotherapy for Esophageal Cancer

  This study is testing if adding a new drug called Toripalimab to standard chemotherapy and radiation can help people with locally advanced esophageal cancer respond better to treatment before surgery.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Baiyun District · NCT06843889

• Comparing two treatments for advanced urothelial carcinoma

  This study is testing if a combination of two treatments can help people with advanced bladder cancer do better than using just one of the treatments alone.

  Recruiting at 2 sites Phase 2 Mabwell (Shanghai) Bioscience Co., Ltd. · Changsha, Hunan and 1 other locations · NCT06823427

• Treatment for advanced extramammary Paget disease of the scrotum

  This study is testing a new combination of two drugs to see if they can help people with advanced HER2-positive extramammary Paget disease of the scrotum feel better and reduce their tumor size.

  Recruiting Phase 2 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06791070

• Combining toripalimab with GemCis for treating resectable intrahepatic cholangiocarcinoma

  This study is testing if combining a new drug called toripalimab with standard chemotherapy can help people with resectable intrahepatic cholangiocarcinoma do better before surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06721286

• Combining chemotherapy and immunotherapy for limited-stage small cell lung cancer

  This study is testing a new treatment that combines chemotherapy and immunotherapy to see if it can help people with limited-stage small cell lung cancer live longer and feel better.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06719700

• Combining Toripalimab and JS004 for treating advanced kidney cancer

  This study is testing if a new combination of two drugs, toripalimab and JS004, can help people with advanced kidney cancer do better than the usual treatment they would receive.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06690697

• Combining chemotherapy with Toripalimab for treating triple negative breast cancer

  This study is testing if combining chemotherapy with Toripalimab can help women with triple negative breast cancer respond better to treatment before surgery.

  Recruiting at 8 sites Phase 2 First Affiliated Hospital of Zhejiang University · Nanchang, Jiangxi and 12 other locations · NCT06682195

• Neoadjuvant treatment for lymph node-positive HR+ breast cancer

  This study is testing if combining a new immunotherapy drug with different types of radiation and chemotherapy can help people with lymph node-positive HR+ breast cancer respond better to treatment before surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06671262

• Evaluating CHS-114 with Toripalimab for Advanced Solid Tumors

  This study is testing a new treatment combining CHS-114 and toripalimab to see if it helps people with advanced stomach or esophageal cancer feel better.

  Recruiting at 28 sites Phase 1 Coherus Oncology, Inc. · Tucson, Arizona and 29 other locations · NCT06657144

• Combining Disitamab Vedotin with RC148 for treating HR-negative, HER2-low breast cancer

  This study is testing if a new combination of two treatments can help people with hard-to-treat HR-negative, HER2-low breast cancer feel better compared to standard options.

  Recruiting Phase 2 RemeGen Co., Ltd. · Beijing, Beijing Municipality · NCT06642545

• Combining All Trans Retinoic Acid with Toripalimab and Chemotherapy for Advanced Triple Negative Breast Cancer

  This study is testing whether a new combination of a vitamin A derivative, an immune therapy, and chemotherapy can help people with advanced triple negative breast cancer.

  Recruiting at 2 sites Phase 2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT06636981

• Neoadjuvant chemotherapy with Toripalimab for HR+/HER2- breast cancer

  This study is testing if adding Toripalimab to standard chemotherapy can help women with HR+/HER2- breast cancer respond better to treatment before surgery.

  Recruiting at 3 sites Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou and 10 other locations · NCT06611813

• Combining targeted radiation with immunotherapy and chemotherapy for advanced laryngeal and hypopharyngeal cancer

  This study is testing a new treatment that combines targeted radiation with immunotherapy and chemotherapy to see if it can help people with advanced laryngeal and hypopharyngeal cancer while preserving their voice box.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06611137

• Combination treatment for advanced Epstein-Barr Virus associated nasopharyngeal carcinoma

  This study is testing a new combination of treatments for people with advanced Epstein-Barr Virus related nasopharyngeal cancer to see if it works better than the usual options.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT06592599

• Combination of 9MW2821 and Toripalimab for advanced bladder cancer

  This study is testing if a new combination of two drugs, 9MW2821 and Toripalimab, can help people with advanced bladder cancer do better than the usual chemotherapy.

  Recruiting Phase 3 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT06592326

• Combining standard therapy with radiotherapy and toripalimab for metastatic colorectal cancer

  This study is testing if adding a new drug called toripalimab and different doses of radiation to standard treatment can help people with metastatic colorectal cancer live longer and feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06525428

• Nimotuzumab with toripalimab plus gemcitabine/cisplatin for first-line recurrent or metastatic nasopharyngeal carcinoma

  This trial tests whether adding nimotuzumab to toripalimab with gemcitabine and cisplatin helps people with first-line recurrent or metastatic nasopharyngeal carcinoma.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06509009

• Combining Toripalimab with Chemotherapy for Recurrent Nasopharyngeal Cancer

  This study is testing if combining a new drug called toripalimab with chemotherapy can help people with recurrent nasopharyngeal cancer feel better.

  Recruiting at 12 sites Phase 4 Coherus Oncology, Inc. · Little Rock, Arkansas and 12 other locations · NCT06457503

• Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors

  This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.

  Recruiting at 3 sites Phase 1 Zumutor Biologics Inc. · Boston, Massachusetts and 2 other locations · NCT06451497

• Neoadjuvant therapy for resectable stage II-III lung cancer

  This study is testing if adding a type of radiation therapy to an immunotherapy drug and chemotherapy can help people with early-stage lung cancer have better surgery results.

  Recruiting Phase 3 Shanghai Chest Hospital · Shanghai · NCT06437977

• Personalized toripalimab therapy for lung cancer based on ctDNA analysis

  This study is testing if using blood tests to check for leftover cancer DNA can help decide if lung cancer patients should get extra treatment with toripalimab after their initial therapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06426511

• Evaluating a new treatment for HR-positive, HER2-low breast cancer

  This study is testing a new treatment combining Disitamab Vedotin and Toripalimab with chemotherapy to see if it helps people with HR-positive, HER2-low breast cancer before surgery.

  Recruiting Phase 2 RemeGen Co., Ltd. · Shanghai, Fudan University Shanghai Cancer Center · NCT06389006

• Neoadjuvant PD-1 blockade for elderly patients with esophageal cancer

  This study is testing a new treatment for older patients with esophageal cancer to see if it can help them have better surgery results and live longer.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT06385730

• Oral all-trans retinoic acid plus toripalimab for advanced or metastatic triple-negative breast cancer

  This test tries whether taking oral all‑trans retinoic acid together with the immunotherapy toripalimab helps people with locally advanced, recurrent, or metastatic triple‑negative breast cancer who have failed at least two prior treatments.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang Province, P.R. China · NCT06371274

• Combining DV and Toripalimab for Kidney Preservation in Patients with Urothelial Carcinoma

  This study is testing a new combination treatment of DV and toripalimab to see if it can help people with kidney problems and bladder cancer keep their kidneys while treating their cancer.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06354231

• Neoadjuvant therapy for bladder cancer patients who can't tolerate cisplatin

  This study is testing a new combination of immune treatments for bladder cancer patients who can't take cisplatin to see if it helps them before surgery.

  Recruiting Phase 1/2 Zhujiang Hospital · Guangzhou, Guangdong · NCT06341400

• Reducing radiation for nasopharyngeal cancer after immunotherapy and chemotherapy

  This study is testing if giving less radiation to patients with nasopharyngeal cancer who have responded well to immunotherapy and chemotherapy can help them feel better while reducing side effects.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT06313450

• Combining Toripalimab with Capecitabine for High-Risk Nasopharyngeal Carcinoma

  This study is testing if combining toripalimab with capecitabine can help high-risk nasopharyngeal cancer patients avoid cancer coming back after their initial treatment.

  Recruiting at 2 sites Phase 3 Jiangxi Provincial Cancer Hospital · Ganzhou, Jiangxi and 2 other locations · NCT06277050

• Using Toripalimab before surgery for advanced lung cancer with specific mutations

  This study is testing if giving a new immunotherapy called Toripalimab before surgery can help people with advanced lung cancer who have specific genetic mutations feel better and improve their chances of recovery.

  Recruiting at 2 sites Phase 2 Ruijin Hospital · Guangzhou, Guangdong and 1 other locations · NCT06269211

• Combination therapy for limited-stage small cell lung cancer

  This study is testing a new combination of immunotherapy and chemotherapy to see if it can help people with limited-stage small cell lung cancer have better treatment results.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT06256237

• Combining Toripalimab with Chemoradiotherapy for Cervical Cancer

  This study is testing if adding an immunotherapy drug called toripalimab to standard treatment can help women with newly diagnosed locally advanced cervical cancer do better than with just the standard treatment alone.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06256224

• Neoadjuvant treatment for HR-negative, HER2 low-expressing breast cancer

  This study is testing a new combination treatment for people with HR-negative, HER2 low-expressing breast cancer to see if it helps them respond better than standard chemotherapy.

  Recruiting Phase 2 RemeGen Co., Ltd. · Changsha, Hunan and 4 other locations · NCT06227117

• Toripalimab treatment for high-risk early-stage lung cancer after surgery

  This study is testing if the immunotherapy drug Toripalimab can help prevent lung cancer from coming back in patients who have just had surgery for early-stage non-small cell lung cancer.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06221670

• Comparing two treatments for advanced liver cancer

  This study is testing if a combination of two treatments for advanced liver cancer can help patients live longer and respond better than just one of the treatments alone.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06201065

• Using Toripalimab after Chemoradiotherapy for Elderly Esophageal Cancer

  This study is testing if the drug toripalimab can help older patients with advanced esophageal cancer feel better and lower their chances of the cancer coming back after they’ve had chemoradiotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06187597

• Combination therapy for HER2-positive breast cancer

  This study tests a new combination of treatments for people with HER2-positive breast cancer to see if it helps them respond better before surgery.

  Recruiting Phase 2 RemeGen Co., Ltd. · Shanghai, Shanghai Municipality · NCT06178159

• Comparing JS004 and Toripalimab to Chemotherapy for Hodgkin Lymphoma

  This study is testing if a new combination of JS004 and Toripalimab can work better than regular chemotherapy for people with Hodgkin lymphoma who haven't responded to previous treatments.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT06170489

• Combination therapy for advanced gastric cancer

  This study is testing a new combination treatment for advanced gastric cancer to see if it works better than the usual options for patients with a specific type of the disease.

  Recruiting Phase 2 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 10 other locations · NCT06155383

• Neoadjuvant therapy for advanced hypopharyngeal cancer

  This study is testing a new combination of immunotherapy and chemotherapy to see if it can help people with advanced hypopharyngeal cancer before they have surgery.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT06151743

• Combining Toripalimab with Cryoablation for Advanced Lung Cancer Treatment

  This study is testing if combining a new immune therapy called toripalimab with a freezing treatment can help people with advanced lung cancer who have had limited growth after their first treatment.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality and 2 other locations · NCT06127303

• Combining WX390 and Toripalimab for Advanced Gastric-type Endocervical Adenocarcinoma with STK11 Mutations

  This study is testing if a new combination of medications, WX390 and Toripalimab, can help people with advanced Gastric-type Endocervical Adenocarcinoma that has STK11 mutations.

  Recruiting Phase 2 Shanghai Jiatan Pharmatech Co., Ltd · Shanghai, Shanghai Municipality · NCT06124963

• Combining WX390 and Toripalimab for advanced solid tumors

  This study is testing if a new combination of two drugs, WX390 and Toripalimab, can safely help people with advanced solid tumors.

  Recruiting Phase 1/2 Shanghai Jiatan Pharmatech Co., Ltd · Changchun, Jilin · NCT06117566

• Evaluating Pimicotinib with Chemotherapy for Advanced Pancreatic Cancer

  This study is testing if a new drug called Pimicotinib, used with chemotherapy, can help people with advanced pancreatic cancer feel better and improve their treatment outcomes.

  Recruiting at 5 sites Phase 2 Abbisko Therapeutics Co, Ltd · Shanghai, Shanghai Municipality and 4 other locations · NCT06111274

• Using toripalimab alone or with tifcemalimab for treating limited-stage small cell lung cancer

  This study is testing if a new combination of two drugs can help people with limited-stage small cell lung cancer feel better after their initial treatment.

  Recruiting at 41 sites Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Harbin, Heilongjiang and 75 other locations · NCT06095583

• Evaluating ABO2011 for advanced solid tumors

  This study is testing a new treatment called ABO2011, alone or with another drug, to see if it can help people with advanced solid tumors feel better and improve their health.

  Recruiting at 5 sites Phase 1/2 Suzhou Abogen Biosciences Co., Ltd. · Beijing and 4 other locations · NCT06088004

• Combining 9MW2821 and Toripalimab for advanced urothelial cancer

  This study is testing if a new combination of two drugs, 9MW2821 and Toripalimab, can help people with advanced bladder cancer feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 Mabwell (Shanghai) Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT06079112

• Combination treatment of toripalimab and actinomycin-D for gestational trophoblastic neoplasia

  This study is testing if combining two drugs, toripalimab and actinomycin-D, can help people with gestational trophoblastic neoplasia respond better than just using actinomycin-D alone.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06028672

• Comparing two treatments for advanced nasopharyngeal carcinoma

  This study is testing a new combination treatment for advanced nasopharyngeal cancer to see if it works better than the standard treatment.

  Recruiting Phase 3 Air Force Military Medical University, China · Xi'an, Shaanxi · NCT06026878

• Using toripalimab and actinomycin-D to treat gestational trophoblastic neoplasia

  This study is testing if a new combination of toripalimab and actinomycin-D can effectively treat gestational trophoblastic neoplasia in patients with a specific score, to see if it works better than standard chemotherapy.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06020755

• Neoadjuvant immunotherapy for localized non-small cell lung cancer with rare mutations

  This study is testing if a combination of a new immunotherapy drug and chemotherapy can help people with localized lung cancer that has rare mutations by seeing if it can completely eliminate the tumor.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guanzhou, Guangdong · NCT05800340

• Postoperative treatment for high-risk non-clear renal cell carcinoma

  This study is testing if a combination of two medications can help prevent the return of non-clear renal cell carcinoma in patients who have just had surgery to remove their tumor.

  Recruiting at 2 sites Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu and 1 other locations · NCT05768464

• Combining chemotherapy with Toripalimab for advanced gastric cancer

  This study is testing if combining a specific chemotherapy with Toripalimab can help people with advanced gastric cancer feel better and improve their treatment results.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang and 7 other locations · NCT05729646

• Evaluating JCXH-212 alone and with Toripalimab for treating malignant solid tumors

  This study is testing a new treatment called JCXH-212, both alone and with another drug called Toripalimab, to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting Early Phase 1 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT05579275

• Combination treatment for advanced intrahepatic cholangiocarcinoma

  This study is testing if a new combination of medications can help people with advanced liver cancer live longer and feel better compared to standard chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT05342194

• Combination treatment for advanced urothelial carcinoma

  This study is testing a new combination treatment for advanced bladder cancer to see if it works better than chemotherapy alone for patients who haven't received treatment before.

  Recruiting at 2 sites Phase 3 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT05302284

• Combining toripalimab with radiotherapy for treating nasopharyngeal carcinoma

  This study is testing if combining a new immunotherapy drug called toripalimab with radiotherapy can help people with nasopharyngeal cancer that has spread, and improve their chances of living longer and feeling better.

  Recruiting at 2 sites Phase 2 Xinqiao Hospital of Chongqing · Chongqing, Chongqing Municipality and 1 other locations · NCT05147844

• Comparing two treatment approaches for advanced oral squamous cell carcinoma

  This study is testing whether a new combination treatment for advanced oral cancer can work better than the standard treatment to help patients before surgery.

  Recruiting Phase 2/3 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT05125055

• Using Toripalimab after surgery and radiation for head and neck cancer

  This study is testing if Toripalimab can help people with advanced head and neck cancer feel better after they have surgery and radiation.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 1 other locations · NCT04992559

• Combining toripalimab with chemotherapy for advanced gastric cancer

  This study is testing if combining a new drug called toripalimab with chemotherapy can help people with advanced stomach cancer do better before surgery.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT04891016

• Neoadjuvant treatment for advanced bladder cancer using Toripalimab with chemotherapy

  This study is testing if a new treatment combining Toripalimab with chemotherapy can help people with advanced bladder cancer before they have surgery.

  Recruiting Phase 2 Zhujiang Hospital · Guangzhou, Guangdong · NCT04861584

• Preoperative treatment for head and neck cancer using Toripalimab with chemotherapy

  This study is testing if the drug Toripalimab, alone or with chemotherapy, can safely help people with head and neck cancer before their surgery.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT04807140

• Combining toripalimab with CAV/IE chemotherapy for advanced soft tissue sarcoma

  This study is testing if adding toripalimab to standard chemotherapy can help people with advanced soft tissue sarcoma who haven't had success with other treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou · NCT04589741

• Using Toripalimab with Chemoradiotherapy for Recurrent Nasopharyngeal Carcinoma

  This study is testing if adding a new drug called Toripalimab to standard chemotherapy and radiation can help people with recurrent nasopharyngeal cancer live longer and feel better during treatment.

  Recruiting Phase 3 Cancer Hospital of Guangxi Medical University · Nanning, Guangxi · NCT04376866

• Comparing treatments for early-stage NK/T cell lymphoma

  This study is testing whether adding a new antibody treatment to the standard therapy helps people with early-stage NK/T cell lymphoma do better.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT04365036

• Comparing immunochemotherapy and chemotherapy for esophageal cancer before surgery

  This study is testing if a new combination of immunotherapy and chemotherapy can help people with esophageal cancer live longer and have better outcomes before surgery compared to standard chemotherapy.

  Recruiting Phase 3 Henan Cancer Hospital · Zhengzhou, Henan · NCT04280822

• Neoadjuvant therapy for colorectal cancer using toripalimab with or without celecoxib

  This study is testing if adding celecoxib to the immunotherapy toripalimab can help people with certain types of colorectal cancer feel better before surgery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT03926338

• Using toripalimab for advanced solid tumors with specific genetic mutations

  This study is testing if toripalimab can help people with advanced solid tumors that have certain genetic mutations feel better and live longer.

  Recruiting at 4 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 3 other locations · NCT03810339

Quick answers

How many clinical trials of Toripalimab are recruiting right now?

121, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 9 countries. The most sites are in China (110 trials), United States (11 trials), Taiwan (2 trials), Canada (1 trial), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 71, Phase 3: 20, Phase 1/2: 12, Phase 1: 6. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →